Secukinumab
- PDF / 151,197 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 25 Downloads / 157 Views
1 S
Secukinumab Paradoxical plaque psoriasis: case report
A 47-year-old woman developed paradoxical plaque psoriasis during treatment with secukinumab for ankylosing spondylitis (AS). The woman, who had a 5 year history of AS and needed systemic methylprednisolone during attacks for symptom relief. Subsequently, she started receiving SC secukinumab 150mg with initial dosing at 0, 1, 2, 3 and 4 weeks, followed by monthly maintenance dosing for 6 months. However, she developed dermatosis on the left foot coincided with the second course of secukinumab treatment. Thereafter, she presented with red, scaly and itchy dry plaques on both of her thighs, legs and arms over 6 months. A dermatological examination showed variably shaped and sized erythematous papules and plaques with silvery scales on the extensor surfaces of the limbs. Her Psoriasis Area and Severity Index (PASI) score was 3.2. She was found to be positive for both antinuclear antibody (ANA) and rheumatoid factor (RF). A histopathology of 4mm punch biopsy (from the dorsum of the left foot) revealed parakeratosis, acanthosis, elongation of rete ridges and a thin granular cell layer consistent with plaque psoriasis. Additionally, lymphocytes predominantly mixed with dermal infiltrate was noted. The woman was then treated with calcipotriol plus betamethasone dipropionate. Her secukinumab therapy was maintained. Subsequently, her psoriasis improved with residual post-inflammatory hyperpigmentation. Durmaz K, et al. Paradoxical plaque psoriasis due to secukinumab treatment in an ankylosing spondylitis patient. Dermatologic Therapy 33: e13504, No. 4, Jul 2020. Available from: URL: http://doi.org/10.1111/dth.13504
0114-9954/20/1823-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803503619
Reactions 26 Sep 2020 No. 1823
Data Loading...
